MENU
+Compare
CERS
Stock ticker: NASDAQ
AS OF
Jun 5 closing price
Price
$1.38
Change
-$0.06 (-4.17%)
Capitalization
342.62M

CERS Cerus Corp Forecast, Technical & Fundamental Analysis

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety... Show more

CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CERS with price predictions
Jun 05, 2025

CERS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CERS turned positive on June 02, 2025. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 03, 2025. You may want to consider a long position or call options on CERS as a result. In of 110 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CERS moved above its 50-day moving average on June 03, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

CERS broke above its upper Bollinger Band on June 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CERS entered a downward trend on June 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.196) is normal, around the industry mean (24.191). P/E Ratio (0.000) is within average values for comparable stocks, (79.080). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.075) is also within normal values, averaging (42.393).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CERS is expected to report earnings to fall 43.75% to -2 cents per share on July 31

Cerus Corp CERS Stock Earnings Reports
Q2'25
Est.
$-0.02
Q1'25
Est.
$-0.04
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.01
The last earnings report on May 01 showed earnings per share of -3 cents, meeting the estimate of -3 cents. With 2.04M shares outstanding, the current market capitalization sits at 342.62M.
A.I. Advisor
published General Information

General Information

a developer of the INTERCEPT Blood System for platelets and plasma

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1220 Concord Avenue
Phone
+1 925 288-6000
Employees
288
Web
https://www.cerus.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGBX41.97N/A
N/A
MFS Core Equity B
GRMRX27.59N/A
N/A
Nationwide S&P 500 Index R
EMEAX12.29N/A
N/A
Ashmore Emerging Markets Equity A
MXIGX14.19N/A
N/A
Empower International Growth Inv
PAINX8.42N/A
N/A
PGIM Jennison Intl Sm-Md Cap Opps Z

CERS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-4.51%
LAB - CERS
52%
Loosely correlated
-7.69%
NNOX - CERS
47%
Loosely correlated
-2.10%
SGHT - CERS
47%
Loosely correlated
-0.83%
ICUI - CERS
46%
Loosely correlated
+1.25%
BFLY - CERS
46%
Loosely correlated
-1.67%
More